Cipher Pharmaceuticals Past Earnings Performance
Past criteria checks 1/6
Cipher Pharmaceuticals has been growing earnings at an average annual rate of 43%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been declining at an average rate of 0.1% per year. Cipher Pharmaceuticals's return on equity is 16%, and it has net margins of 59.9%.
Key information
43.0%
Earnings growth rate
44.4%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | -0.1% |
Return on equity | 16.0% |
Net Margin | 59.9% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Cipher Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 26 | 16 | 9 | 0 |
30 Jun 24 | 22 | 23 | 6 | 0 |
31 Mar 24 | 22 | 23 | 6 | 0 |
31 Dec 23 | 21 | 20 | 5 | 0 |
30 Sep 23 | 21 | 32 | 5 | 0 |
30 Jun 23 | 20 | 28 | 5 | 0 |
31 Mar 23 | 20 | 27 | 5 | 0 |
31 Dec 22 | 21 | 27 | 5 | 0 |
30 Sep 22 | 22 | 10 | 5 | 0 |
30 Jun 22 | 21 | 8 | 5 | 0 |
31 Mar 22 | 22 | 9 | 5 | 0 |
31 Dec 21 | 22 | 8 | 5 | 0 |
30 Sep 21 | 22 | 5 | 6 | 0 |
30 Jun 21 | 23 | 6 | 6 | 0 |
31 Mar 21 | 21 | 3 | 6 | 0 |
31 Dec 20 | 22 | 4 | 6 | 0 |
30 Sep 20 | 21 | 7 | 6 | 0 |
30 Jun 20 | 22 | 3 | 5 | 0 |
31 Mar 20 | 23 | 4 | 6 | 0 |
31 Dec 19 | 22 | 3 | 8 | 0 |
30 Sep 19 | 23 | -1 | 11 | 0 |
30 Jun 19 | 22 | 2 | 13 | 0 |
31 Mar 19 | 23 | 3 | 14 | 1 |
31 Dec 18 | 23 | 1 | 14 | 1 |
30 Sep 18 | 28 | 6 | 13 | 1 |
30 Jun 18 | 34 | 9 | 13 | 0 |
31 Mar 18 | 37 | 11 | 13 | 0 |
31 Dec 17 | 40 | 11 | 13 | 0 |
30 Sep 17 | 34 | 7 | 13 | 0 |
30 Jun 17 | 32 | 5 | 13 | 0 |
31 Mar 17 | 31 | 1 | 14 | 1 |
31 Dec 16 | 30 | 4 | 16 | 1 |
30 Sep 16 | 33 | 6 | 23 | 1 |
30 Jun 16 | 34 | 2 | 28 | 0 |
31 Mar 16 | 34 | 1 | 29 | 0 |
31 Dec 15 | 34 | 2 | 29 | 1 |
30 Sep 15 | 32 | 3 | 21 | 1 |
30 Jun 15 | 30 | 13 | 14 | 1 |
31 Mar 15 | 30 | 18 | 10 | 1 |
31 Dec 14 | 29 | 19 | 9 | 1 |
30 Sep 14 | 33 | 31 | 7 | 1 |
30 Jun 14 | 32 | 27 | 7 | 1 |
31 Mar 14 | 29 | 25 | 7 | 0 |
31 Dec 13 | 25 | 24 | 6 | 0 |
Quality Earnings: PHE has a high level of non-cash earnings.
Growing Profit Margin: PHE's current net profit margins (59.9%) are lower than last year .
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PHE has become profitable over the past 5 years, growing earnings by 43% per year.
Accelerating Growth: PHE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PHE had negative earnings growth (-51.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (28.7%).
Return on Equity
High ROE: PHE's Return on Equity (16%) is considered low.